Patent · US Active

Treatment to render implants resistant to diabetes

US9283241B2 · kind B2 · utility

3Cited by

36References

14Claims

0Family size

Assignee

Clemson University · US

Inventors

Agneta Simionescu · Pendleton, US
Dan Simionescu · Pendleton, US
James Chow · Paradise Valley, US

Key dates

Filing date	Jul 10, 2013
Grant date	Mar 15, 2016
Priority date	—
Expiry date	Sep 18, 2033

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61L2430/20
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed is a medical device treated with a phenolic compound and a process for treating a device with the phenolic compound. For example, a collagen or elastin-based scaffold can be treated with pentagalloyl glucose (PGG). The treated scaffold can become resistant to glycoxidative stress associated with advanced glycation end products (AGEs) that are present in a hyperglycemic environments associated with diabetes mellitus. The treated scaffold can exhibit a reduced increase in stiffness as compared to an untreated scaffold. The treated scaffold can also exhibit reduced inflammation without negatively affecting the ability of the scaffold to remodel in vivo.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.